Bortezomib (a proteasome inhibitor) has recently been approved for treatment of relapsed multiple myeloma, a plasma cell neoplasia, owing to the sensitivity of immunoglobulin-synthesizing myeloma ...
Extramedullary plasmacytomas at pancreatic head and pleura. Management. Salvage chemotherapy regimens including bortezomib plus steroid, alkylators plus steroid, bortezomib plus anthracycline and ...
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
Hosted on MSN1mon
GSK's belantamab mafodotin reduced death risk by 42% in studyThe study is evaluating belantamab mafodotin in combination with bortezomib plus dexamethasone, or BVd, versus daratumumab in combination with bortezomib plus dexamethasone, or DVd, as a second ...
Discover all the brand names or Trade names of generic drug called Bortezomib. This serves as a crucial reference for healthcare professionals, patients, caregivers, and anyone looking to ...
Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Pomalidomide Newbury in Denmark as the first country in a Scandinavian registration procedure. Approvals i ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback